The Government of Uttar Pradesh has taken a big step to make the state the top center of the country in Pharma, Biotech and Medical Device Fields. On Friday (July 18) at Lal Bahadur Shastri Bhavan in Lucknow, Uttar Pradesh Promot Pharma Council signed two important agreement (MOU) with the Uttar Pradesh Promot Pharma Council with Translative Health Science and Technology Institute (THSTI) and Indian Institute of Technology (IIT-BHU) of Varanasi. Their purpose is to help research, new ideas, startups support and skill development.

The event was chaired by Principal Secretary of Medical Education IAS Partha Sarathi Sen Sharma. In his speech, he said that Uttar Pradesh is now ready to become the leader of the country in Pharma and Health-Tech. These agreement will be a game-changer in bringing together research, product development, technology transfer, startups and policy making together.

What happened in the agreement?

The agreement took place between Uttar Pradesh Promot Pharma Council and Testi Faridabad. After this, a second agreement was signed with IIT-BHU Varanasi. Members of both institutes promised long -term partnerships to support research, new products, training and startups in Pharma, Biotech and Healthcare Technology.

Experts and officers said this

Pharma Field Expert Dr. GN Singh said that these agreement will give new direction to research and new ideas in Uttar Pradesh. There is a need to focus on the necessary areas and bring the results quickly. At the same time, Advisor to the Chief Minister Avnish Kumar Awasthi said that these agents will play a big role in achieving the target of $ 1 trillion economy, bulk drug park and medical device park. The work of drug manufacturing unit in medical device park and Lalitpur on Yamuna Expressway is going on fast. These steps will also boost investment, policy making and global partnership.

Such is the planning of future

Managing director and CEO IAS Kritika Sharma of Uttar Pradesh Promot Pharma Council said that there is time to make Uttar Pradesh innovation hub in Pharma, Biotech and Health-Tech. Through these agents, we are taking strong and planned steps. In this event, Dr. Nitya Wadhwa of Medical Education Secretary Aparna U, Thhti, Sushant Kumar Srivastava of IIT-BHU and Prof. Rajesh Kumar etc. were also involved.

Also read: If these 5 exercises do daily liver will never be fatty, you will feel fit, you will feel perfectly

Disclaimer: Some information given in the news is based on media reports. Before implementing any suggestion, you must consult the concerned expert.

Check out Below Health Tools-
Calculate your body mass index (BMI)

Calculate the age through age calculator

There is going to be a big explosion in the pharma industry! Torrent Pharmaceuticals of Ahmedabad are now preparing to create history. A step that will make it India’s second largest pharma company. Come, know about this historical deal. Ahmedabad pharmaceutical company Torrent Pharma is going to buy large stake in JB Chemicals and Pharmaceuticals. And this deal will be around ₹ 19,500 crores … After this deal, Torrent Pharma will become the second largest pharma company in India. Earlier, in 2015, Sun Pharma made the biggest record of the industry by purchasing Ranbaxy. But now, this step of Torrent Pharma is going to create a new stir in the sector. Let’s deal ki details ko vistaar se samjhe toh …. pehla hain ki 46.39% will be purchased from America’s PE Company KKR, and for this the torrent will spend about ₹ 11,917 crore. Will go Aur Teesra Hain Ki After this, Torrent will have to bring an open offer for 26% shares, which will be around ₹ 6,842.8 crore …

If your portfolio has Pharma stocks, then these news is very important for coming because there may be many big announcements. Us President Donald Trump is not taking the name of the Tariff. Trump applied 26% tariff rate on India but kept the Pharma Sector untouched but 8 April the Donald Trump itself announced the installation of tariffs on Pharmaceutical Companies and since which has been a tension in Pharma Companies. This tariff will affect both India and US countries. Indian pharma manufacturers earn from 30% to 50% from American Market. Let us talk about India’s 4 Indian Pharmaceutical Firms, whose stocks can be on high risk due to the tariff. So Dr Reddy’s Laboratories, Aurobindo Pharma, Zydus Lifescienes and Sun Pharma. Will it be right to buy these stocks during this Trade War, watch the video to know.